Ginkgo Bioworks Holdings (DNA)

NYSE
3.440
+0.300(+9.55%)
  • Volume:
    25,121,313
  • Day's Range:
    3.260 - 3.510
  • 52 wk Range:
    2.090 - 15.864

DNA Overview

Prev. Close
3.14
Day's Range
3.26-3.51
Revenue
539.12M
Open
3.32
52 wk Range
2.09-15.864
EPS
-1.95
Volume
25,121,313
Market Cap
5.98B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
25,069,082
P/E Ratio
-
Beta
-
1-Year Change
-72.72%
Shares Outstanding
1,731,175,535
Next Earnings Date
Nov 14, 2022
What is your sentiment on Ginkgo Bioworks?
or
Vote to see community's results!

Ginkgo Bioworks Holdings News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Ginkgo Bioworks Holdings Analysis

Ginkgo Bioworks Holdings Company Profile

Ginkgo Bioworks Holdings Company Profile

Industry
Chemicals
Sector
Materials
Employees
641

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Read More

Analyst Price Target

Average7.407 (+114.39% Upside)
High12
Low3
Price3.455
No. of Analysts7
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyBuyStrong BuyStrong BuySell
Technical IndicatorsBuyStrong BuyStrong BuyStrong BuyStrong Sell
SummaryStrong BuyStrong BuyStrong BuyStrong BuyStrong Sell
  • 1.71 billion shares at 3.10... LOL
    0
    • arkinvest went all in with DNA
      0
      • Disaster
        2
        • Cathie W has left the chat room...
          5
          • ark bought a lot ot stocks
            0
          • Cathie is a fraud
            3
        • What is going on?
          0
          • Ginkgo Bioworks says third quarter revenue was up, acknowledges investment firm report triggered a federal inquiryThe Boston company also reported a $26.7 million loss for the period, down from $34.4 million last year.
            0
            • here we go again
              0
              • DNA (T) 1 13.35
                1
                • eat the dust scorpion analytics!!
                  1
                  • shorted by some clueless funds
                    1